<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382408</url>
  </required_header>
  <id_info>
    <org_study_id>DR-ADV-301</org_study_id>
    <nct_id>NCT00382408</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
      safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory
      disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at two sites and will include a minimum of 4 visits. The overall
      study duration for participants will be approximately 8 weeks. Study participants will
      undergo acute respiratory disease evaluation that will include a throat swab and a blood
      draw. Each participant will also be contacted in six months for follow-up information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the per protocol cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56</measure>
    <time_frame>Day 11 - Day 56</time_frame>
    <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort; further, this outcome omitted ARD cases from Day 0-Day 10 because the protective effect of the vaccine was unlikely to take place during that time period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Showing ADV-7 Seroconversion at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>ADV-7 seroconversion was defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-7 titer was &lt;1:4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Showing ADV-4 Seroconversion at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>ADV-4 seroconversion was defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-4 titer was &lt;1:4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>For the oral Type-4 vaccine, the number of cases of ADV-4 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Showing ADV Type-4 Booster at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>ADV-4 booster effect is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-4 titer is ≥1:4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>For the oral Type-7 vaccine, a secondary outcome is the number of cases of ADV-7 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>For the oral Type-7 vaccine, the number of cases of ADV-7 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Showing ADV Type-7 Booster at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>ADV-7 booster effect is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-7 titer is ≥1:4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4040</enrollment>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DR-5001</intervention_name>
    <description>All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Military recruit in training

          -  Male or female; if female, must be of non-childbearing potential or with a documented
             negative pregnancy test &lt;/= 72 hours prior to study medication administration and
             agree not to become pregnant

        Exclusion Criteria:

          -  Female nursing an infant or planning on nursing during the study

          -  Immunosuppressed for any reason, including past (within last 6 months) or current
             treatment with immunosuppressive therapy

          -  Known allergy to any component of the vaccines and/or placebo tablets

          -  Immunocompromised sexual partner or immunocompromised individuals in home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Great Lakes</city>
        <state>Illinois</state>
        <zip>60088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Fort Jackson</city>
        <state>South Carolina</state>
        <zip>29207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <results_first_submitted>July 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2012</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute respiratory disease prevention</keyword>
  <keyword>Adenovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in subjects undergoing military basic training.</recruitment_details>
      <pre_assignment_details>Participants were randomized to either the vaccine group or the matching placebo group in a 3:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3031"/>
                <participants group_id="P2" count="1009"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2887"/>
                <participants group_id="P2" count="955"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet protocol requirement</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3031"/>
            <count group_id="B2" value="1009"/>
            <count group_id="B3" value="4040"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="4.0"/>
                    <measurement group_id="B2" value="21.1" spread="4.1"/>
                    <measurement group_id="B3" value="21.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" lower_limit="17.1" upper_limit="42.0"/>
                    <measurement group_id="B2" value="19.7" lower_limit="17.1" upper_limit="42.2"/>
                    <measurement group_id="B3" value="19.8" lower_limit="17.1" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1121"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="1488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1910"/>
                    <measurement group_id="B2" value="642"/>
                    <measurement group_id="B3" value="2552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="554"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1871"/>
                    <measurement group_id="B2" value="642"/>
                    <measurement group_id="B3" value="2513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3031"/>
                    <measurement group_id="B2" value="1009"/>
                    <measurement group_id="B3" value="4040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type-4 Titer</title>
          <description>Negative = titer value &lt;1:4 Positive = titer value &gt;=1:4</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1906"/>
                    <measurement group_id="B2" value="678"/>
                    <measurement group_id="B3" value="2584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1123"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="1454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type-7 Titer</title>
          <description>Negative = titer value &lt;1:4 Positive = titer value &gt;=1:4</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1159"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1870"/>
                    <measurement group_id="B2" value="632"/>
                    <measurement group_id="B3" value="2502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
        <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
        <time_frame>Day 0 - Day 56</time_frame>
        <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
          <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
          <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3031"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The vaccine efficacy (VE) was defined as: VE = 1 - R, where R = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccines compared to placebos (Blackwelder 1993). The 95% confidence interval of the VE was obtained by inverting the Chi Square method proposed by Koopman for the ratio of two binomial proportions (Koopman 1984). The goal of the analysis of efficacy was to demonstrate a VE of at least 80% with a lower 95% confidence bound at least 60%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>vaccine efficacy (VE)</param_type>
            <param_value>99.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.02</ci_lower_limit>
            <ci_upper_limit>99.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort</title>
        <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the per protocol cohort.</description>
        <time_frame>Day 0 - Day 56</time_frame>
        <population>The per-protocol (PP) cohort included all participants who met the eligibility criteria set forth in the protocol, did not have any significant violations or deviations from the protocol, and completed the final study visit (Day 56). Subjects who vomited within 24 hours after taking the study medication were excluded from the PP cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort</title>
          <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the per protocol cohort.</description>
          <population>The per-protocol (PP) cohort included all participants who met the eligibility criteria set forth in the protocol, did not have any significant violations or deviations from the protocol, and completed the final study visit (Day 56). Subjects who vomited within 24 hours after taking the study medication were excluded from the PP cohort.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2855"/>
                <count group_id="O2" value="945"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56</title>
        <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort; further, this outcome omitted ARD cases from Day 0-Day 10 because the protective effect of the vaccine was unlikely to take place during that time period.</description>
        <time_frame>Day 11 - Day 56</time_frame>
        <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56</title>
          <description>For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort; further, this outcome omitted ARD cases from Day 0-Day 10 because the protective effect of the vaccine was unlikely to take place during that time period.</description>
          <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3031"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Showing ADV-7 Seroconversion at Week 4</title>
        <description>ADV-7 seroconversion was defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-7 titer was &lt;1:4.</description>
        <time_frame>Week 4</time_frame>
        <population>Type-7 ADV Seroconversion Cohort: Included those subjects who had a negative Type-7 ADV serum neutralizing antibody status at baseline (&lt;1:4) and at least one titer value for ADV-7 at the subsequent visits following vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Showing ADV-7 Seroconversion at Week 4</title>
          <description>ADV-7 seroconversion was defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-7 titer was &lt;1:4.</description>
          <population>Type-7 ADV Seroconversion Cohort: Included those subjects who had a negative Type-7 ADV serum neutralizing antibody status at baseline (&lt;1:4) and at least one titer value for ADV-7 at the subsequent visits following vaccination.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1120"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="92.4" upper_limit="95.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.0" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Showing ADV-4 Seroconversion at Week 4</title>
        <description>ADV-4 seroconversion was defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-4 titer was &lt;1:4.</description>
        <time_frame>Week 4</time_frame>
        <population>Type-4 ADV Seroconversion Cohort: Included those subjects who had a negative Type-4 ADV serum neutralizing antibody status at baseline (&lt;1:4) and at least one titer value for ADV-4 at the subsequent visits following vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Showing ADV-4 Seroconversion at Week 4</title>
          <description>ADV-4 seroconversion was defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-4 titer was &lt;1:4.</description>
          <population>Type-4 ADV Seroconversion Cohort: Included those subjects who had a negative Type-4 ADV serum neutralizing antibody status at baseline (&lt;1:4) and at least one titer value for ADV-4 at the subsequent visits following vaccination.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1841"/>
                <count group_id="O2" value="653"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="93.4" upper_limit="95.5"/>
                    <measurement group_id="O2" value="10.6" lower_limit="8.2" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
        <description>For the oral Type-4 vaccine, the number of cases of ADV-4 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
        <time_frame>Day 0 - Day 56</time_frame>
        <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
          <description>For the oral Type-4 vaccine, the number of cases of ADV-4 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.</description>
          <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3031"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The vaccine efficacy (VE) was defined as: VE = 1 - R, where R = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccines compared to placebos (Blackwelder 1993). The 95% confidence interval of the VE was obtained by inverting the Chi Square method proposed by Koopman for the ratio of two binomial proportions (Koopman 1984). The goal of the analysis of efficacy was to demonstrate a VE of at least 80% with a lower 95% confidence bound at least 60%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>vaccine efficacy (VE)</param_type>
            <param_value>98.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.39</ci_lower_limit>
            <ci_upper_limit>99.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Showing ADV Type-4 Booster at Week 4</title>
        <description>ADV-4 booster effect is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-4 titer is ≥1:4.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Type-4 ADV Booster Cohort included subjects who had a positive Type-4 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-4 at the subsequent visits following study medication administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Showing ADV Type-4 Booster at Week 4</title>
          <description>ADV-4 booster effect is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-4 titer is ≥1:4.</description>
          <population>Type-4 ADV Booster Cohort included subjects who had a positive Type-4 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-4 at the subsequent visits following study medication administration.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1094"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" lower_limit="47.3" upper_limit="53.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
        <description>For the oral Type-7 vaccine, a secondary outcome is the number of cases of ADV-7 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
        <time_frame>Day 0 - Day 56</time_frame>
        <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
          <description>For the oral Type-7 vaccine, a secondary outcome is the number of cases of ADV-7 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
          <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3031"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
        <description>For the oral Type-7 vaccine, the number of cases of ADV-7 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
        <time_frame>Day 0 - Day 56</time_frame>
        <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort</title>
          <description>For the oral Type-7 vaccine, the number of cases of ADV-7 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.</description>
          <population>The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3031"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Showing ADV Type-7 Booster at Week 4</title>
        <description>ADV-7 booster effect is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-7 titer is ≥1:4.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Type-7 ADV Booster Cohort included subjects who had a positive Type-7 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-7 at the subsequent visits following study medication administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Showing ADV Type-7 Booster at Week 4</title>
          <description>ADV-7 booster effect is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-7 titer is ≥1:4.</description>
          <population>Type-7 ADV Booster Cohort included subjects who had a positive Type-7 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-7 at the subsequent visits following study medication administration.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1815"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="43.8" upper_limit="48.4"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 (vaccination day) - Day 56</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
        <group group_id="E2">
          <title>Vaccine</title>
          <description>Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>BRONCHITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>INTENTIONAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>LIGAMENT INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>STRUCK BY LIGHTNING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER WITH ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER WITH DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER WITH MIXED ANXIETY AND DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>CYCLOTHYMIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PERSONALITY DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="916" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2673" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="216" subjects_affected="175" subjects_at_risk="1009"/>
                <counts group_id="E2" events="593" subjects_affected="482" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="142" subjects_affected="112" subjects_at_risk="1009"/>
                <counts group_id="E2" events="484" subjects_affected="387" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="246" subjects_affected="193" subjects_at_risk="1009"/>
                <counts group_id="E2" events="654" subjects_affected="552" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="77" subjects_affected="68" subjects_at_risk="1009"/>
                <counts group_id="E2" events="209" subjects_affected="181" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="56" subjects_affected="55" subjects_at_risk="1009"/>
                <counts group_id="E2" events="86" subjects_affected="84" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="1009"/>
                <counts group_id="E2" events="146" subjects_affected="139" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="490" subjects_affected="424" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1361" subjects_affected="1193" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="134" subjects_affected="131" subjects_at_risk="1009"/>
                <counts group_id="E2" events="493" subjects_affected="475" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="372" subjects_affected="270" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1070" subjects_affected="787" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="57" subjects_affected="55" subjects_at_risk="1009"/>
                <counts group_id="E2" events="113" subjects_affected="110" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="79" subjects_affected="72" subjects_at_risk="1009"/>
                <counts group_id="E2" events="254" subjects_affected="233" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="659" subjects_affected="447" subjects_at_risk="1009"/>
                <counts group_id="E2" events="1795" subjects_affected="1237" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="294" subjects_affected="238" subjects_at_risk="1009"/>
                <counts group_id="E2" events="855" subjects_affected="685" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="273" subjects_affected="226" subjects_at_risk="1009"/>
                <counts group_id="E2" events="927" subjects_affected="740" subjects_at_risk="3031"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="271" subjects_affected="233" subjects_at_risk="1009"/>
                <counts group_id="E2" events="912" subjects_affected="743" subjects_at_risk="3031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In the past 6 years, Type-7 ADV has only rarely been recovered from recruits with ARD (Russell 2007). Therefore, it may not be possible to directly measure the protective effect of the vaccine against Type-7 ADV in the proposed study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products, R&amp;D Inc.</organization>
      <phone>215-591-3000</phone>
      <email>info.era-clinical@teva.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

